Ardelyx Q3 2022 net loss $22.9M; IBSRELA sales $4.9M; expects $35M Japan milestone

ARDELYX, INC.

2022-Q3 EPS reported -$0.53 revenue$7,980,000

Net loss of $22.9M ($0.14 per share) versus $43.6M ($0.42) in Q3 2021; narrowed 47%.
IBSRELA net product sales of $4.9M for Q3 2022, six months into launch.
Cash, equivalents and investments $90.6M at Sept 30, 2022, down from $116.7M at Dec 31, 2021.
Kyowa Kirin submitted tenapanor NDA in Japan; Ardelyx expects aggregate $35M milestones in Q4 2022.
FDA Advisory Committee for XPHOZAH (tenapanor) scheduled for November 16, 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ARDELYX, INC. reported the fiscal quarter ended September 30, 2022 results: net income Net loss for the quarter ended September 30, 2022 was $22.9 million, or $(0.14) per share, EPS $(0.14) per share.

Period: the fiscal quarter ended September 30, 2022
Net income: Net loss for the quarter ended September 30, 2022 was $22.9 million, or $(0.14) per share
EPS: $(0.14) per share
Result: reported results

Exact text from the filing

On November 3, 2022, Ardelyx, Inc. (the “Company”) announced its financial results for the fiscal quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

ARDELYX, INC. filing history →

Source: SEC EDGAR

accession 0001628280-22-028174

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.